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Chronic infection with Hepatitis B virus (HBV) is a major risk factor for the development of 
advanced liver disease including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The relative 
contribution of virological factors to disease progression has not been fully defined and tools aiding 
the deconvolution of complex patient virus profiles is an unmet clinical need. Variable viral mutant 
signatures develop within individual patients due to the low-fidelity replication of the viral polymerase 
creating ‘quasispecies’ populations. Here we present the first comprehensive survey of the diversity 
of HBV quasispecies through ultra-deep sequencing of the complete HBV genome across two distinct 
European and Asian patient populations. Seroconversion to the HBV e antigen (HBeAg) represents 
a critical clinical waymark in infected individuals. Using a machine learning approach, a model was 
developed to determine the viral variants that accurately classify HBeAg status. Serial surveys of 
patient quasispecies populations and advanced analytics will facilitate clinical decision support for 
chronic HBV infection and direct therapeutic strategies through improved patient stratification.
HBV is a relaxed circular, partially double-stranded DNA virus, with a unique genomic organization (four over-
lapping reading frames encoding 7 proteins in 3.2 kb) and replication mechanism. The low-fidelity reverse tran-
scriptase (1.45-7.9e-05 per site/year - non-synonymous vs synonymous mutations1) and the high replication rate 
(1e12 virions/day) means that a single progeny virus may not be identical to the parent genome in a single infected 
cell2. This generates a viral ecosystem consisting of mutant swarms or ‘quasispecies’, a population of genetically 
distinct, but closely related viral variants3–5. HBV quasispecies, therefore, comprise a spectrum of viral variants 
with differing fitness, which allows for the rapid adaptation to selective pressures including host immune factors 
and antiviral agents6,7. Consequently, HBV variants have an impact (if positively selected to sufficient abundance) 
on disease pathogenesis, clinical progression, and response to therapeutic interventions8–11. Frequently reported 
estimates for infection prevalence (4%), absolute number of infected individuals (257 million), and annual mor-
tality (887000) demonstrate the large global burden of disease attributable to HBV12,13. Together with hepatitis C 
virus (HCV), viral hepatitis represents the leading cause of hepatocellular carcinoma14,15.
HBV e antigen is a secreted precore protein of Hepatitis B virus with an unclear viral function16, but with high 
sequence conservation across hepadenaviruses17. Seroconversion to this antigen and subsequent antigen loss 
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(HBeAg negative status, anti-HBe positive phase) is associated with reduced viral replication and diminished 
long-term complications, for example, the risk of hepatocellular carcinoma18. Progression to seroconversion, 
either spontaneous or treatment-induced, may take years; contemporary studies have demonstrated differential 
rates of seroconversion associated with the duration and type of therapeutic regimen in addition to individual 
patient clinical profiles19,20. All virological factors associated with HbeAg seroconversion have not been elucidated 
and deeper knowledge of these may aid the definition of patients likely to seroconvert and direct appropriate 
therapeutic strategies.
In addition to HBV DNA load, ALT levels, HBV surface antigen (HBsAg), the loss of plasma HBeAg and 
seroconversion to HBeAg represent valuable clinical waymarks of a functional cure21. The plasma levels of these 
markers are used as proxies of viral activity in the liver; inferences about the spectrum of viral quasispecies in 
plasma reflecting those in hepatocytes has not been qualitatively assessed. Furthermore, HBeAg negative patients 
may have ongoing complex clinical profiles the virological basis of which has not been established.
The progression of chronic hepatitis B is related to the prevailing viral and host immune activities. The toler-
ogenic activity of HBeAg facilitates the establishment of HBV infection in vivo - this tolerance to infection is lost 
during the anti-HBe positive phase and immune-escape HBeAg-negative mutants may be selected22. Increased 
sequence diversity, associated with stochastic mutations, can result in changes in immune tolerance and reactivity 
with concomitant changes in selection pressure and evolution of the virus. The dynamic interplay and drivers of 
viral evolution are complex and difficult to resolve linearly; the use of advanced analytic tools may assist in the 
deconvolution of the prevailing virological factors that contribute to serocoversion.
Many studies have disclosed variants with statistical associations with clinical metrics in different regions of 
the HBV genome23–26, but associations between all variants in all HBV coding regions and clinical parameters 
has not been established. For example, the nG1896A (W28*) mutation in the precore and nA1762T/nG1764A 
double mutation in the basal core promoter have temporal correlations with seroconversion and have been shown 
to be associated with different clinical courses3,11. Next generation sequencing (NGS) technologies are optimal 
for uncovering the spectra of variants that exist within an infected individual and in the wider population for 
disease surveillance and healthcare planning27. Ultra-deep NGS enables the detection of viral variants at low 
allele frequency with much greater sensitivity and confidence. To date most studies have focused on particular 
regions of the HBV genome, e.g. HBs major hydrophilic region (MHR)28, core29, and reverse transcriptase (RT)30 
or on whole genome sequencing9 at low coverage and, most recently, on single virions31. Here we present the first 
comprehensive survey of the diversity HBV quasispecies through ultra-deep sequencing of the complete HBV 
genome across two distinct patient populations and, in addition, explore quasispecies diversity between plasma 
and liver samples.
The use of big data advanced analytics is an emergent field with potential for extensive application in health-
care32,33 including applications where there is disease and treatment heterogeneity and for prescriptive analyt-
ics (precision medicine and clinical decision support). The current paradigm for classification of HBV infected 
patients utilises a series of virological and biochemical factors to infer viral activity and liver damage, as well as 
histopathological analysis of liver biopsies for fibrosis scoring (Fig. 1). In complex viral disease profiles, where 
single laboratory tests may not provide sufficient insight into the clinical history and progression of a patient 
advanced analytic techniques, including machine learning, may unlock insights into host and pathogen factors 
that may represent novel biomarkers for prognostics and therapeutic strategies. Consideration of advanced ana-
lytics applied to complex disease of virological origin has not been extensively evaluated - this study sought to 
investigate the feasibility of combining big data and advanced analytics to drive clinical insight in chronic hepa-
titis B infection.
Machine Learning (ML) encompasses a field of data-driven techniques for the study and construction of 
predictive algorithms that allow classification of factors/classes or estimation of quantitative traits from com-
plex, multi-dimensional data (hundreds to thousands of co-variates) without a priori models34. In essence, ML 
approaches identify patterns revealing novel relationships between covariates or allow inferences to be made 
about future events. We have applied a random forest machine learning approach to classify the HBeAg status of 
untreated patients with chronic HBV infection using the standard HBeAg diagnostic test as a benchmark. Using 
the allele frequency of HBV variants we identify novel associations between viral variants and HBeAg status. Our 
analysis demonstrates a proof-of-concept of the utility of machine learning approaches to classify HBV infected 
patients and offers the prospect of exploring additional markers for therapeutic decision making and prognostic 
support.
Methods
Patients and samples. Patient samples were derived from two retrospective cohorts representing a sin-
gle point in time for each patient; the first, a Western European cohort defined as Dataset A, the second, a 
Chinese cohort, defined as Dataset B, Table 1. In both cases the collection of patient samples was undertaken 
with informed and written consent and in accordance with the Declaration of Helsinki. Metadata (demographic 
and clinical data) was anonymized at point of collection and all data analysis was undertaken blinded and 
without access to patient identification keys. Projects were reviewed and authorized by the respective ethical 
review boards (Dataset A: Erasmus Medical Centre, Rotterdam, The Netherlands; Dataset B: Ethics Committee 
of Xiamen Centre for Disease Control and Prevention). Dataset A was derived from plasma samples (n = 182) 
consecutively collected from chronic HBV patients between 1985 and 2012 and stored at the Erasmus University 
Medical Centre, Rotterdam, The Netherlands. Dataset B plasma samples (n = 207 samples) were collected from 
patients with chronic HBV infection attending the Zhongshan Hospital, Xiamen University, China between 2013 
and 2016. Patient inclusion criteria in Dataset B related to age (20 to 79 years old) and HBV DNA levels (≥107 
copies/ml).
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Diagnosis. For Dataset A serum HBeAg was quantified in samples taken at baseline using the Elecsys® 
HBeAg assay (Roche Diagnostics, range 0.2–100 IU/ml). HBV infection of patients was assessed using com-
mercial enzyme-linked immunosorbent assay kits. Paired liver biopsies (collection procedure was undertaken 
Figure 1. Study summary and motivation. Patients infected with HBV have complex and dynamic clinical 
profiles. The diagnostic and clinical decision paradigm (dashed box) in HBV infected patients involves 
classification by plasma markers of viral activity (a) and biochemical and histopathological (b) evidence of 
liver damage. This approach defines patients broadly into four classes that will inform the clinical decision 
for standard-of-care including the use of interferon and/or nucleoside analogues. Using virus whole genome 
sequencing to catalogue all nucleotide variants occurring at >1% machine learning approaches are explored 
to determine whether classification of HBeAg status could be recapitulated from a diverse patient population, 
extend our understanding of the virological factors associated with HbeAg status and evaluate whether this 
type of approach may be extended to novel markers of clinical status that will inform clinical decision making 
for stratification of patients in clinical trials and in the appropriate patient selection for use of next-generation 
treatment modalities for HBV. The study sought to answer three questions (solid boxes): Q1 - that plasma HBV 
quasispecies profiles were representative of those in the liver; Q2 – that machine learning approaches could 
accurately recapitulate classification by a routinely used clinical marker; and Q3 – whether this approach has 
wider utility in clinical decision support and the deconvolution of complex clinical history.
Description Dataset A Dataset B
Gender
Female 55 67
Male 127 140
Duration of infection (years) 33.2 (±13.2) Unknown*
Age at inclusion (years) 35.5 (±13.5) 30.6 (±7.2)
HBV DNA load (log10 copies/mL) 6.74 (±1.96) 7.75 (±0.46)
AST (IU/mL) 53.1 (±33.07) 134.7 (±125.3)
ALT (IU/mL) 87.8 (±80.02) 265.4 (±272.9)
HBeAg status
negative 85 26
positive 97 181
Treatment
naive 182 170
established 0 37
Table 1. Summary descriptors for patients included in the study. Datasets A and B represent the European and 
Asian cohorts respectively. Pertinent demographic, virological and biochemical data are provided. Continuous 
data is provided as the mean and standard deviation for the appropriate dataset. The duration of infection was 
not available for the Asian cohort as a result of the nature of standard presentation of patients in the recruiting 
clinic. *Estimated duration of infection unavailable.
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as previously described35) and plasma were obtained from ten patients in accordance with the approved study 
protocol. For Dataset B the HBV infection of patients was confirmed by using commercial enzyme-linked immu-
nosorbent assay kits (Wantai BioPharm, Beijing, China) and quantified by using real-time fluorescence quan-
titative PCR. Patient liver biochemistry and virological metrics (serum qualitative HBsAg, anti-HBs, HBeAg, 
anti-HBeAg, HBV viral load) at baseline was obtained from the respective electronic medical records.
Deep-sequencing. The ultra-deep sequencing of HBV samples was conducted by DDL Diagnostic 
Laboratory (Dataset A, Rijswijk, Netherlands) and by Guangzhou Kingmed Diagnostics (Dataset B, Guangzhou, 
China). Multiplexed paired-end sequencing was performed on the Illumina MiSeq platform using the MiSeq v2 
sequencing kit with 300 cycles for both sample populations. Demultiplexed FASTQ files were generated as an 
output. A complete description of workflow is provided in Supplementary Materials and Methods.
Data analysis pipeline. The sequencing analysis pipeline was implemented in python (Python 2.7, 
12.05.2015). All further data analysis, machine learning, phylogenetic and statistical analysis (including 
Shannon entropy and majority voting analysis) and graphical plot generation was performed in R (Release 3.4.1, 
30.06.2017), The R Foundation for Statistical Computing) – a full list of software packages and methods are pro-
vided in Supplementary Materials and Methods.
Sequencing analysis pipeline. Nucleotide sequences for reference genotypes were obtained from NCBI 
(https://www.ncbi.nlm.nih.gov/nuccore) with the following accessions: genotype A (AF090842); B (AB033554); 
C (AB033556); D (AF121240); and E (AB032431). FASTQ files were obtained from Illumina sequencing plat-
form output for all samples. A full description of the sequencing analysis pipeline is provided in Supplementary 
Materials and Methods and Supplementary Fig. 2.
Machine learning. To classify HBeAg status from viral mutant signatures for both datasets only samples 
from untreated patients were used (n = 182 Dataset A; n = 170 Dataset B) to limit effects on sample variant profile 
attributable to treatment methods. The input to the machine learning was a matrix of viral variant allele frequen-
cies (0.01–0.99) and the associated HBeAg status (‘positive’ or ‘negative’) as defined by standard diagnostic tests. 
A random forest machine learning approach was employed to establish the variants that best classified HBeAg 
status. A series of test and training partitions and cross-validation steps were undertaken to optimize the model 
before testing against independent data excluded from model generation. Comparison of random forest models 
was based upon the following metrics: accuracy, balanced accuracy, sensitivity, specificity, and kappa values. For 
Figure 2. Allele frequency differences between liver and plasma. (A) Percentage differences (y-axis) in allele 
frequency between variants found more abundantly in the plasma (red points, positive values) or liver (blue 
points, negative values); HBV genome nucleotide positions defined by the x-axis. (B) Cumulative frequency 
plot for difference (>1%) in allele frequency for variants in n = 10 paired liver and plasma samples - each trace 
represents the running total trace for the frequency of variants with a defined difference in a allele frequency 
between liver and plasma samples. The majority of variants found in liver and plasma only show small 
differences in the adjusted allele frequency (1–2 percentage points) as demonstrated by the steep rise of traces in 
most patients. Few variants (n = 56) show differences >10% across all samples.
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the combined dataset (Datasets A and B: n = 352 samples and n = 5533 unique variants) variants with near-zero 
variance were excluded leaving n = 432 variants. Full descriptions of the machine learning approach are provided 
in Supplementary Materials and Methods and Supplementary Fig. 3.
Figure 3. Graphical overview of the distribution of samples from both datasets. Dataset A (A) consisted 
of n = 182 patients; Dataset B (B) was derived from n = 207 patients. The overlap of variants identified 
between different genotypes for Dataset A (C, Venn plot not scaled) demonstrated n = 208 variants common 
to genotypes A–D). In Dataset B genotypes B and C shared a larger number of variants (D). Frequency 
distribution - the majority of variants were either rare or uncommon with an adjusted allele frequency above 
the limit of detection (1%) or represented the most prevalent allele in the samples (E). (F) Violin plots show the 
distribution of variants within each genotype with frequency of variant occurrence within a genotype presented 
as the coverage (count/number of samples) where 1 represents a variant present in all samples of the same 
genotype (upper limits of the plot). Variants at the lower limits of the plots were rare and unique mutations and 
represented the sequence diversity in a genotype.
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Results
Comprehensive survey of HBV variants. Supplementary tablers liver HBV variants. To investigate 
whether plasma samples sufficiently represent the hepatic quasispecies population paired liver biopsy and plasma 
samples were collected as part of Dataset A (n = 10). The frequency of HBV variants found in either the liver or 
plasma were compared to define systematic differences in the quasispecies populations. The majority of variants 
demonstrated small differences in allele frequency (1–2%), as shown in Fig. 2A. A small number of variants 
(n = 56) demonstrated a difference of 10% or greater. These differences between plasma and liver populations 
were found to be patient-associated, i.e. the majority of patients demonstrated only small differences in allele 
frequency between the tissues (Fig. 2B), whilst one patient accounted for the majority of variants showing large 
differences in allele frequency (Supplementary Table 2a,b).
Quasispecies diversity arises from rare and unique viral variants. Dataset A (n = 182 patients) represented a 
cohort of diverse ethnic background from Western Europe. The dataset consisted of five HBV genotypes (A-E); 
all samples were obtained from untreated patients. A graphical overview of Dataset A is presented in Fig. 3A. 
Variants with an adjusted allele frequency greater than 1% were used for analysis. A total of 4615 variants were 
detected above this threshold and used as features to predict HBeAg status (Fig. 3C). In the absence of HBsAg 
levels it was not possible to classify the clinical status of these patients by EASL guidelines21. Dataset B was derived 
exclusively from an ethnically Chinese (Han) patient cohort. After filtering Dataset B represented n = 207 patients 
of whom n = 170 were treatment naïve; a further n = 37 received either treatment with a nucleoside analogue or 
interferon therapy (Fig. 3B). Using the EASL (European Association for the Study of the Liver) guidelines all 
samples from this cohort were classed as ‘chronic hepatitis’. Dataset B was comprised of genotypes B and C; a total 
of n = 3039 variants were defined at >1% frequency with n = 1245 variants common to both genotypes (Fig. 3D). 
The intersection of genotypes B and C found n = 1640 variants common to both datasets (Jaccard Index = 0.45).
Dataset Gene
Amino Acid 
alteration Nucleotide
Allele 
Frequency
Absolute Number 
of Samples Genotype
Resistance 
association
A RT Leu80Ile 367T > A 0.72 1/19 B L
A RT Val84Met 379G > A 0.13–0.16 1/62 D A
1/43 C
A RT Asn238Asp 841A > G 0.02–0.99 6/43 C A/L
0.17 1/56 A
A RT Ala181Thr 670G > A 0.02–0.06 3/62 D A/L/Tb/Tf
Ala181Val 671C > T 0.02 1/62
A RT Met204Ile 741G > T <0.02 3/62 D L/Tb ± E,A
0.01 1/43 C
0.02 1/56 A
741G > T/C 0.01/0.73 2/19 B
A RT Val214Ala 770T > C 0.02–0.05 4/62 D A/Tf
0.34 1/56 A
0.02/0.05 2/43 C
Val214Glu 770T > A 0.08 1/43 C
B RT Val173Leu 646G > C/T 0.09/0.04 1/37 C L/E
646G > C 0.01 1/133 B
B RT Ala181Thr 670G > A 0.01 1/133 B A/L/Tb/Tf
0.24 1/23A B
0.02 1/14E C
B RT Ala194Thr 709G > A 0.04 1/133 B Tf
B RT Met204Ile 741G > T 0.98 1/23A B L/Tb/Tf
B RT Val214Ala 770T > C 0.04 1/14E C A/Tf
0.02 1/14IFN C
0.03 1/133 B
0.02/0.04 2/37 C
Val214Glu 770T > A 0.8 1/14IFN C
B RT Asn238Asp 841A > G 0.02–0.03 3/37 C A/L
Table 2. Drug Resistance-Associated Mutations and associated allele frequencies. In Dataset B patients 
receiving treatments are highlighted as a superscript letter in column 5 (absolute numbers of patients). Amino 
acid changes and related nucleotide positions are provided. The allele frequency for a mutation relative to the 
reference genomes is provided as a range where the mutation was found in more than two patients. In some 
individuals more than one mutation is present at the same locus. Abbreviations for therapeutics: A – Adefovir; 
E – Entecavir; IFN – Interferon; L – Lamivudine; Tf – Tenofovir; Tb – Telbivudine.
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Viral variant heterogeneity differs with genotype. The average number of variants per patient and per genotype 
was considered for Dataset A (genotypes A-E represented). In general, within a viral genotype most variants 
were found only once across all the patients, Fig. 3E and Supplementary Fig. 4. To consider the overlap between 
patients across genotypes and define ‘genotype-associated’ variants we considered variants occurring at least 
twice within a genotype (Fig. 3F). Genotype D demonstrated the greatest sequence diversity with low variant 
coverage, i.e. few variants found consistently in all patient samples. Significant differences in Shannon entropy 
between HBeAg status groups was also noted (Supplementary Materials & methods; Supplementary Figs. 5–7)
Variants associated with drug resistance present in untreated patients. Low frequency mutations aid viral adap-
tation to selection pressures and so are particularly relevant to development of drug resistance and treatment 
failure36. Genomic variants in the reverse transcriptase/polymerase (RT/POL) gene, leading to amino acid 
substitutions conferring single and multi-drug resistance, were found in plasma samples of untreated patients 
in both datasets (Table 2). Drug-resistance associated mutations were found in 15–17% of patient samples 
from genotype B and D in dataset A. Patients infected with HBV genotype C demonstrated the most frequent 
resistance-associated variants in Dataset A (26%) and Dataset B (16% untreated; 29% treated).
Phylogenetic analysis recapitulates genotype groups across cohorts. Consensus whole genome nucleotide 
sequences were gathered for each patient plasma sample for each dataset (Dataset A, n = 182; Dataset B, n = 207), 
paired plasma and liver samples (n = 10) variant profiles if present (total samples, n = 399), and five reference 
genomes (genotypes A-E) for phylogenetic analysis. Genotypes B and C grouped together in the appropriate 
clades, Fig. 4, regardless of geographical origin. The remaining Dataset A samples from genotypes A, D, and E also 
grouped together in their appropriate clades alongside the reference genomes used for mapping of sequencing 
reads. Despite the extensive sequence diversity recorded and clinical heterogeneity phylogenetic clades resolved 
entirely by genotype across the two datasets.
Machine learning defines novel viral variants classifying HBeAg status. Defining classifier variants 
for HBeAg status. Machine learning was used to define patterns of viral variant allele frequencies that demon-
strated a strong association with HBeAg status and would act as robust classifiers and uncover novel virological 
factors. A model with a balanced accuracy of 1 (Accuracy, Sensitivity, and Specificity = 1) was found using test 
data from Dataset A (range balanced accuracy 0.8–1), Fig. 5A,B, although the relative contribution of each variant 
to classification accuracy was small. The highest-ranking variables contributing to this model included known 
pre-core and basal core promotor mutants (n1896GA, n1934AT, n1753TC). In general, the variants with greatest 
relevance to the model were found in the precore/core region, with some variants found in the HBsAg, X or RT/
POL genes. The majority of variants were mis-sense, with nG1896A and nC2351T defined as stop gains.
Viral variant allele frequencies from Datasets A and B were combined (n = 352 samples and n = 2119 common 
variants). This represented a low overlap of shared variants across datasets (Jaccard index = 0.38). Random forest 
Figure 4. Circular cladogram based on n = 404 whole genome consensus nucleotide sequences. Phylogenetic 
analysis on sequences from n = 192 Dataset A (including 10 liver sample sequences), n = 207 Dataset B, and 
n = 5 reference strains. Figure key indicates genotype (by colour) and data source (by size and shape). Reference 
strains are defined by a ‘+’ and highlighted with dark-coloured arrow heads. Samples derived from n = 10 liver 
biopsies in Dataset A are defined by squares.
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classification of HBeAg status utilised samples from treatment naïve patients from both cohorts with n = 100 
HBeAg negative and n = 252 HBeAg positive samples. The most accurate models were achieved when variants 
with near-zero variance were excluded from combined dataset leaving n = 432 variants for machine learning. The 
best performing model had a balanced accuracy of 0.98 (accuracy = 0.97; sensitivity = 0.96; specificity = 1; kappa: 
0.93) against test data derived from both data sets (0.9/0.1 ratio of train/test data), Fig. 5C,D. By combining the 
datasets the relative contribution of each variant to classification accuracy to improved and altered the ranking 
of the variants with the greatest contribution. The distribution of the top-ranking variants in the HBV genome is 
presented in Fig. 6A,B. Using this model to classify HBeAg status of the additional n = 37 samples (HBeAg status: 
n = 10 negative; n = 27 positive) from treated patients (not seen in the training of the model) was highly accurate 
(balanced accuracy = 1).
Conclusions
Hepatitis B virus has a baseline mutation rate of 1–7 e-05 base mutations/year and this diversity is fundamental 
to an understanding of the associations with the course of clinical disease, mutational dynamics, evaluation of 
novel strains, susceptibility to therapeutic interventions and development of immunity27. We report the first study 
to undertake ultra-deep sequencing of the whole HBV genome in almost 400 patients from two distinct cohorts. 
Ultra-deep sequencing demonstrated that, in general, variants arising within a single patient represented unique 
or rare mis-sense mutations that occur at the level of detection for the platform used (>1%). A subset of variants 
Figure 5. Highest ranking variants in machine learning model. (A,C) –Plots of the mean decrease in Gini 
Index for top 20 variables contributing to the best-performing models for Dataset A (5A) and combined data 
(5C); (B,D) – Plots of model metrics from each of ten models developed from Dataset A (5B) or combined 
dataset (Dataset A and B) (5D). Variants nomenclature: e.g. n1896GA represents a G > A mutation at 
nucleotide position 1896. (A) Gini plot of variant importance based on n = 4215 variants from Dataset A data 
associated with Model F (B). Model achieves a balanced accuracy of 1 with defined data partitioning. Variants 
highlighted in orange represent the stop-gain mutation (G1896A) and the two mutations of the basal core 
promoter (G1764A and A1762T). (C) Gini plot for top 20 variants contributing to the model developed from 
n = 432 variants to predict HBeAg status combining samples from untreated patients in Datasets A and B. The 
best model accuracy found in Model A (balanced accuracy = 0.98), (D). Variants depicted in grey (4C) were 
common to both datasets; those represented in orange were the mutations defined in Dataset A alone and are 
genotype-associated.
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were found exclusively or with high frequency within the distinct genotypes. Differences were evident between 
genotypes in terms of the heterogeneity of viral populations with genotype D samples revealing greater sequence 
diversity with many low frequency mutants within individuals and more variation between patients than geno-
type A; greater similarity was evident between genotypes B and C.
The quasispecies populations of paired liver and plasma samples were analysed in a small patient cohort 
(n = 10). Few variants demonstrated a differential allele frequency greater than 10 percentage points between 
liver and plasma; we concluded that plasma samples represented an adequate proxy for inferring the diversity in 
the viral quasispecies population in chronically infected patients. In work by Nishijima and colleagues37, to deter-
mine the correspondence of hepatic quasispecies with plasma populations in patients undergoing liver trans-
plantation, no differences in Shannon entropy was found. Likewise, no significant differences have been found 
between multiple paired liver samples and plasma in HCV-infected patients38. Coffin, et al., reported location and 
disease phase-specific differences in variants39 although limited differences were found between liver, polymor-
phonuclear cells (PBMCs) and plasma over an extended period of analysis10. This corroboration of quasispecies 
populations in liver and plasma supports the further investigation of plasma biomarkers to evaluate the presence 
of disease-associated variants.
Contemporary sequencing studies have focused on particular regions of the HBV genome, e.g. HBs MHR28, 
core29, and RT30, or small whole genome sequencing studies9. Using ultra-deep sequencing, with high coverage, of 
the complete HBV genome we employed a random forest algorithm40, an ensemble method that builds ‘forests’ of 
binary decision trees to improve the classification accuracy of weak predictors, to define HBeAg status in patients 
across genotypes and demographics. Although machine learning approaches have been applied recently for virus 
data41–43 these methods have been applied sporadically to HBV41,44–46. The analysis presented here demonstrates 
the utility of unbiased, data-driven approaches to reveal novel aspects of HBV biology. Harnessing the power of 
two cohorts ML defined patterns of viral variant allele frequencies that accurately classified HBeAg status that 
was not possible from a single dataset; this model contained both variants with known temporal associations with 
HBeAg seroconversion, confirming the validity of the approach, and novel variants that aided the discrimination 
of HBeAg status that would not have been discovered by traditional statistical approaches.
HBe loss has a temporal correlation with elevated frequencies of a precore mutation at nG1896A and/or 
nG1764A/nA1764T basal core promotor mutations47 although these mutations are not present in all genotypes/
sub-genotypes during seroconversion22. The ML models confirmed nG1896A as the most predictive mutation 
in classifying the HBeAg status of chronically infected HBV patients. Additionally, we note the strong contri-
bution from nA1934T, nC2501T, nG1899A in HBeAg classification together with genotype-associated variants. 
The combined models included nC2501T, an intergenic variant found exclusively in genotype A in Dataset A at 
an allele frequency >0.91 in patients (n = 58) of both HBeAg classes. This variant is not associated with the six 
nucleotide insertion in genotype A. This highlights genotype specific discrimination in the combined model 
where the majority of samples were genotype B (n = 187). Similarly, the nA1934T precore/core variant was asso-
ciated with genotype A, D and E samples and not found in genotype B and C samples in either dataset indicating 
another genotype partition in the combined model. The nA1934T mutation is reflected in a Thr12Ser amino acid 
substitution and is a mutation within the MHC class II restricted T-cell epitope (CD4 + Th epitope 1–20) in the 
core protein48,49 known to be associated with clinical reactivation during lamivudine treatment50 and HCC51. This 
Figure 6. Circos plots depict distribution of high-ranking variants across HBV genome. Dataset A genotypes B 
and C. From outer to inner layer: Circos plot representing the HBV genome (layer 1) genotypes B and C (3215 
nucleotides); layer 2–4: representation of the relative position of the transcribed genes; layer 5: mean entropy 
for each nucleotide position (0–0.15) with y/vertical-axis marks representing the following: 0, 0.03, 0.06 and 
0.09 (outer to inner); layer 6: Read coverage per nucleotide position (maximum 60000) – vertical axis, (i) 5000 
(red), (ii) 10000 (green), (iii) 20000, iv) 30000; layer 7: individual nucleotide position for the top 50 ranked 
variants contributing to the generic machine learning model for prediction of HBeAg status; layer 8: nucleotide 
positions of variants, found in untreated patients, associated with resistance to therapeutics. Arrows define the 
approximate location of the proprietary primers used. (B) Circos plot generated from dataset B follows the same 
topology as plot A. Gene annotation is provided by the colour key.
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suggests that these variants contribute to partitioning of genotypes with subsequent classification of HBeAg status 
by the frequency of nG1896A, nG1899A, nG1764A/A1764T mutations.
This study identifies novel patterns of viral variants associated with existing HBeAg status, however, makes no 
inference about the mechanism by which this status was reached (no historical clinical data) or what the model 
means with respect to patient outcomes (data was not part of a longitudinal study). Equally, we cannot comment 
on patient profiles that are not represented in the study population, e.g. HBeAg negative inactive carriers with 
low HBV DNA loads. The ML model was formed on the known HBeAg status as defined by standard diagnostic 
techniques, i.e. the development of an alternative diagnostic test was not the intent of this study. Although we 
present a classification model with high discriminative accuracy this does not translate directly to changes in 
clinical practice and decision support. To make such a model applicable we require prospective studies with 
serial sampling to capture patients in the process of seroconversion and follow treatment groups. Further, such a 
model requires to be calibrated to the population of interest (e.g. our study uses two clinical cohorts with differing 
healthcare approaches) and be applied to a clear risk-sensitive decision point in the clinical setting (e.g. change in 
therapeutic regimen)52. We are, however, encouraged by the performance of the general model in discriminating 
HBeAg status in the n = 37 patients receiving treatment from the Dataset B cohort which served as an independ-
ent test group. By including a diverse sample population for feature-selection it was possible to establish a general 
model for HBeAg classification with broad relevance to the clinical population. Furthermore, we characterize 
the incidence of resistance-associated mutants in naïve patients; previous work has shown the presence of these 
mutants in naïve patients30,53 and our work further supports the future requirement for baseline sequencing of 
infected individuals to tailor therapeutic regimens.
The utility of ML approaches to clinical decision making in infectious diseases is not currently widely appre-
ciated, however, the application of deep sequencing and ML analysis to identify data patterns could facilitate the 
targeting of specific therapeutic interventions to high risk groups, aid stratification of patients for more effective 
clinical trial design, link models to clinical decision support tools and, through incorporating patient demo-
graphic data, facilitate epidemiological and healthcare planning through a deeper understanding of the rela-
tionship between compound factors27,32,33,54. Our study demonstrates that plasma HBV quasispecies adequately 
represent the viral populations within hepatocytes and that these profiles, when interrogated with machine learn-
ing approaches, can recapitulate classification of patients by clinical marker status in addition to revealing novel 
biology.
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